Alpha-synuclein transgenic mouse models are essential tools for studying the pathogenesis of Parkinson's disease (PD) and related alpha-synucleinopathies. These genetic models overexpress wild-type or mutant human alpha-synuclein (encoded by the SNCA gene), recapitulating key features of human disease including Lewy body-like pathology, progressive neurodegeneration, and both motor and non-motor phenotypes.
| Model |
Promoter |
Expression Level |
Phenotype Severity |
Availability |
| Thy1-aSyn |
Thy1 |
High |
Moderate-severe |
Jackson Labs, Taconic |
| PDGF-β-aSyn |
PDGF-β |
Moderate |
Moderate |
Custom |
| CMV-aSyn |
CMV |
Variable |
Mild-moderate |
Custom |
| mThy1-aSyn |
mThy1 |
High |
Severe |
Jackson Labs |
The Thy1-driven model (Thy1-aSyn) shows robust expression in cortical and subcortical neurons, with age-dependent formation of phosphorylated alpha-synuclein inclusions and progressive motor deficits. The mThy1 promoter provides even stronger neuronal expression.
The A53T mutation (SNCA p.A53T) was first identified in the Italian Contursi kindred and the German family. Mouse models expressing human A53T alpha-synuclein under various promoters exhibit:
- Accelerated pathology: Earlier onset of inclusions compared to wild-type
- Severe motor phenotype: Progressive motor dysfunction starting around 8-12 months
- Extensive neuronal loss: Degeneration in substantia nigra, cortex, and spinal cord
- Prion-like propagation: Evidence of templated aggregation in recipient mice
Available Strains:
- B6;C3H-Tg(Prnp-SNCA*A53T)83Vle/J (Jackson Labs)
- Tg(Prp-SNCA*A53T) line M83
The A30P mutation (SNCA p.A30P) was identified in a German family. Key features:
- Reduced fibril formation: A30P shows slower aggregation kinetics in vitro
- Variable in vivo pathology: Less robust inclusion formation compared to A53T
- Mitochondrial dysfunction: Notable mitochondrial pathology
- Motor impairment: Mild to moderate motor deficits
The E46K mutation (SNCA p.E46K), identified in Basque families, creates models with:
- Enhanced aggregation: Increased propensity for oligomer formation
- Severe Lewy pathology: Extensive inclusion formation
- Behavioral deficits: Both motor and cognitive impairment
- Sleep disorders: REM sleep behavior disorder-like phenotypes
¶ H50Q and G51D Mutations
Additional models include:
- H50Q: Identified in sporadic PD cases; intermediate aggregation
- G51D: Found in Finnish families; combines features of A53T and A30P
flowchart TD
A["Transgene Expression<br/>hSNCA under<br/>Promoter"] --> B["Alpha-Synuclein<br/>Overexpression"]
B --> C["Post-Translational<br/>Modifications"]
C --> D["Phosphorylation<br/>pSer129"]
C --> E["Ubiquitination"]
C --> F["Truncation"]
D --> G["Oligomerization"]
E --> G
F --> G
G --> H["Fibril Formation"]
H --> I["Lewy Body-like<br/>Inclusions"]
I --> J["Neuronal Dysfunction"]
J --> K["Progressive<br/>Neurodegeneration"]
¶ Lewy Body-Like Pathology
Alpha-synuclein transgenic mice develop cytoplasmic inclusions that share key features with human Lewy bodies:
- Phosphorylated alpha-synuclein: Major constituent (at pSer129)
- Ubiquitin positive: Similar to human inclusions
- Neuronal localization: Predominantly in soma and neurites
- Age-dependent progression: Pathology increases with age
| Brain Region |
Pathology Type |
Onset |
| Substantia nigra pars compacta |
Dopaminergic neuron loss |
12-18 months |
| Cortex |
Pyramidal neuron dysfunction |
9-15 months |
| Hippocampus |
Synaptic degeneration |
12-18 months |
| Brainstem |
Motor neuron involvement |
15-24 months |
Transgenic models show reactive gliosis accompanying neurodegeneration:
- Microglial activation: Increased Iba1 and CD68 staining
- Astrocytic reactivity: GFAP upregulation
- Cytokine release: TNF-α, IL-1β, IL-6 elevation
| Test |
Measure |
Typical Findings |
| Rotarod |
Motor coordination |
Decreased latency to fall |
| Cylinder |
Forelimb asymmetry |
Increased ipsilateral use |
| Pole test |
Bradykinesia |
Increased descent time |
| Gait analysis |
Step length, stride |
Reduced stride length |
| Grid walk |
Foot faults |
Increased errors |
| Challenging beam |
Traversal |
Increased slips |
- Morris water maze: Spatial memory impairment
- Novel object recognition: Reduced discrimination index
- Y-maze: Reduced spontaneous alternation
- Barnes maze: Spatial learning deficits
- Gastrointestinal transit: Delayed gastric emptying
- Cardiovascular: Orthostatic hypotension
- Urinary: Bladder dysfunction
- Body weight: Progressive weight loss
- REM sleep behavior disorder: REM without atonia
- Sleep fragmentation: Increased awakenings
- Circadian rhythm disturbances: Altered activity patterns
Alpha-synuclein transgenic mice are used to test:
- Aggregation inhibitors: Small molecules targeting oligomer/fibril formation
- Immunotherapies: Active vaccines and passive antibodies
- Gene therapy: AAV vectors delivering SNCA shRNA or miRNA
- Cellular clearance enhancers: Autophagy and lysosomal modulators
- Neuroprotective agents: Mitochondrial protectants, antioxidants
- CSF biomarkers: Validate alpha-synuclein, tau, and neurodegeneration markers
- Imaging biomarkers: Test PET ligands for alpha-synuclein pathology
- Peripheral biomarkers: Blood and skin biopsy markers
- Propagation studies: Investigate prion-like spreading via inoculation
- Cell-type vulnerability: Identify why dopaminergic neurons are selectively affected
- Interaction networks: Map protein-protein interactions in disease
Transgenic models primarily represent genetic (familial) PD, particularly:
- SNCA multiplication: Overexpression mimics gene duplication/triplication
- Dominant toxicity: Mutant expression shows gain-of-function mechanisms
To model sproadic PD, researchers combine:
- Age-related factors: Aged mice show more severe pathology
- Environmental stressors: MPTP, rotenone exposure
- α-synuclein preformed fibrils: Inoculation to initiate pathology
- Viral vectors: Targeted expression in specific regions
| Target |
Intervention |
Model Used |
| Alpha-synuclein reduction |
ASO, siRNA |
Thy1-aSyn |
| Aggregation inhibitors |
Small molecules |
A53T, A30P |
| Immunotherapy |
Active/passive immunization |
Thy1-aSyn |
| GCase enhancement |
GCase activators |
A53T |
| LRRK2 inhibition |
LRRK2 inhibitors |
Thy1-aSyn × LRRK2 G2019S |
Key findings from mouse models that informed clinical trials:
- Immunotherapy: Anti-α-synuclein antibodies reduced inclusions in mouse brain (NCT03272166, PRX002)
- Aggregation inhibitors: NPT200-11 and related compounds progressed to clinical testing
- Gene therapy: AAV-mediated SNCA knockdown approaches validated in mice
- Oligomer modulators: Anle138b showed promise in mouse models
- Mouse vs. human physiology: Differences in protein clearance pathways
- Lifespan: Accelerated pathology may not reflect human disease timeline
- Brain structure: Subtle differences in neuronal circuits
| Limitation |
Impact |
| No true Lewy bodies |
Ultrastructural differences |
| Incomplete penetration |
Not all mice develop severe pathology |
| Variable expression |
Transgene copy number variation |
| Background strain |
C57BL/6 vs. mixed background effects |
- Therapeutic window: Doses effective in mice may not translate
- Pharmacokinetics: Species differences in drug metabolism
- BBB penetration: Not all compounds cross blood-brain barrier similarly
- Masliah et al., 2000 - Synucleinopathy in transgenic mice
- Giasson et al., 2002 - A53T alpha-synuclein transgenic mice
- Lee et al., 2002 - Regional expression of mutant alpha-synuclein
- Unger et al., 2006 - Thy1-alpha-synuclein model characterization
- Luk et al., 2012 - Induction of Lewy pathology by preformed fibrils
- Games et al., 2013 - Large animal model comparison
- Chatterjee et al., 2023 - Alpha-synuclein transgenic models review
- Breydo et al., 2012 - Alpha-synuclein misfolding and aggregation
- Spillantini et al., 1997 - Alpha-synuclein in Lewy bodies
- Lücking & Brice, 2000 - Cell models for Parkinson's disease